2026-07-07 | Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA(TM) for Adult Patients with Primary IgA Nephropathy | NDAQ:VERA | Press Release
Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of progression. In ORIGIN 3 interim analysis, TRUTAKNA reduced proteinuria (UPCR) 46% vs baseline and 42% vs placebo at 36 weeks (p<0.0001). Common AEs were infections and local reactions; long-term kidney benefit not yet established.
How this was made
The 30-second read
Why it matters
FDA granted accelerated approval based on a prespecified interim analysis showing substantial UPCR (proteinuria) reduction vs placebo at 36 weeks; confirmatory evidence on kidney function (eGFR) is still expected in Q3 2026.
Market read
This is a primary regulatory catalyst with quantified interim efficacy and a clear next milestone (Q3 2026 eGFR readout), making it actionable for biotech traders.
What to watch
Safety details are limited to interim trial experience; investors may scrutinize infection/local reaction rates and any emerging immunogenicity or long-term tolerability as the program matures.
Background
TRUTAKNA is a BAFF and APRIL inhibitor (atacicept-vymj) targeting immunological drivers of IgA nephropathy; ORIGIN 3 is the ongoing Phase 3 registrational program.
Ticker impact
Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) in primary IgA nephropathy, with interim proteinuria results vs placebo.
Likely positive near-term repricing on approval; follow-through depends on investor focus shifting to Q3 2026 eGFR readout and confirmatory benefit.
The article discloses a first-in-class accelerated approval decision plus specific interim efficacy (UPCR reductions) and safety, which typically drives immediate sentiment and valuation changes for biotech.
Market effects
Strengthens the BAFF/APRIL pathway validation in IgA nephropathy and may raise expectations for competing immunology-driven nephrology programs.
Primarily US-focused regulatory catalyst; could influence sentiment across US-listed biotech peers in nephrology/autoimmune kidney disease.
IgA nephropathy is global; approval may accelerate international adoption discussions and competitive positioning worldwide.
Counterpoint
Because accelerated approval is contingent on confirmatory kidney-function benefit, the market may later discount the stock if the Q3 2026 eGFR results are weaker than proteinuria signals imply.
Key entities
- companyVera Therapeutics, Inc.
Nasdaq-listed commercial-stage biotech that announced FDA accelerated approval for TRUTAKNA in primary IgA nephropathy.
- drugTRUTAKNA (atacicept-vymj)
BAFF and APRIL inhibitor administered 150 mg subcutaneously once weekly via autoinjector.
- clinical_trialORIGIN 3 trial
Ongoing randomized, double-blind, placebo-controlled Phase 3 trial; interim analysis at 36 weeks supported accelerated approval.
- regulatorU.S. Food and Drug Administration (FDA)
Granted accelerated approval contingent on verification/description of clinical benefit in ongoing ORIGIN 3.
